YOLFTbeta
Caribou Biosciences Inc

Caribou Biosciences Inc

CRBU · NASDAQ · Healthcare / Biotechnology

0.3619USD-0.02 (-4.81%)

Price History

Full chart

Market Stats

Previous Close0.3802
Open0.3835
Day Range0.36 – 0.3835
52-Week Range1.22 – 3.54
Volume1.74M
Market Cap134.01M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.08
Dividend Yield0.00%
Beta2.28
50-Day Avg1.54
200-Day Avg1.76

About

Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Rachel E. Haurwitz Ph.D.
  • Employees97
  • Headquarters2929 7th Street, Berkeley, CA, United States, 94710, USA
  • Websitehttps://cariboubio.com

Leadership

  • Dr. Rachel E. Haurwitz Ph.D.Co-Founder, CEO, President & Director · b. 1986
  • Mr. Sriram Ryali M.B.A.Chief Financial Officer · b. 1982
  • Ms. Barbara G. McClung Esq., J.D.Chief Legal Officer & Corporate Secretary · b. 1955
  • Dr. Jennifer A. Doudna Ph.D.Co-founder & Member of Scientific Advisory Board · b. 1964
  • Mr. Ryan FischesserInterim Principal Accounting Officer & Controller
  • Ms. Reigin ZawadzkiChief People Officer
  • Dr. Tina Albertson M.D., Ph.D.Chief Medical Officer · b. 1974

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue5.79M12.36M9.60M13.85M34.48M9.99M11.16M
Growth (%)-+113.56%-22.35%+44.31%+148.91%-71.01%+11.66%
Cost of Revenue23.64M34.42M984.00K3.64M3.52M3.93M3.65M
Gross Profit5.79M-22.06M8.61M10.21M30.95M6.07M7.51M
Gross Margin100.00%-178.50%89.75%73.71%89.78%60.71%67.34%
Operating Expense40.09M14.06M75.59M116.61M147.01M172.68M143.71M
Operating Income-34.30M-36.12M-66.98M-106.40M-116.06M-166.62M-136.19M
Operating Margin-592.69%-292.24%-697.84%-768.17%-336.63%-1667.16%-1220.49%
EBITDA-30.21M-35.21M-65.61M-95.71M-98.35M-145.19M-145.03M
EBITDA Margin-521.99%-284.82%-683.58%-691.00%-285.27%-1452.74%-1299.67%
Net Income-23.43M-34.31M-66.92M-99.42M-102.07M-149.10M-148.13M
Net Income Margin-404.82%-277.55%-697.26%-717.79%-296.05%-1491.95%-1327.40%
R&D23.64M34.42M52.26M82.23M112.08M130.15M109.44M
R&D as % of Total Revenue408.34%278.50%544.44%593.68%325.07%1302.31%980.72%
Interest Expense4.00K20.00K8.00K8.54M---
Interest Expense % of Total Revenue0.07%0.16%0.08%61.63%---

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets61.93M36.05M442.36M373.76M432.21M313.31M175.37M
Total Liabilities54.47M59.48M54.53M72.89M63.81M60.36M53.19M
Total Equity7.46M-23.44M387.82M300.87M368.40M252.95M122.17M
Cash41.07M15.95M240.42M58.34M51.16M16.29M12.36M
Total Debt532.00K1.58M259.00K27.75M27.11M26.49M27.23M
Net Debt-40.54M-14.38M-240.42M-30.59M-24.05M10.19M14.87M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-32.01M-33.22M-32.52M-90.97M-93.29M-138.20M-110.99M
Investing Cash Flow27.23M6.36M-176.40M-93.25M-68.18M86.61M102.24M
Financing Cash Flow172.00K1.74M433.43M2.13M154.30M16.72M4.82M
Capital Expenditure884.00K1.31M3.12M7.05M11.61M6.50M1.36M
Free Cash Flow-32.89M-34.53M-35.64M-98.02M-104.90M-144.71M-112.35M
FCF to OCF102.76%103.96%109.60%107.75%112.45%104.71%101.22%

Earnings

Report DateMar 31, 2020Mar 31, 2021Jun 2, 2021Sep 2, 2021Nov 9, 2021Mar 21, 2022May 9, 2022Aug 9, 2022Nov 8, 2022Mar 9, 2023May 9, 2023Aug 8, 2023Nov 7, 2023Mar 11, 2024May 7, 2024Aug 6, 2024Nov 6, 2024Mar 10, 2025May 8, 2025Aug 12, 2025Nov 12, 2025Mar 16, 2026May 7, 2026Aug 13, 2026Nov 11, 2026
EPS Estimate0.000.00-0.930.42-0.24-0.36-0.34-0.36-0.48-0.46-0.49-0.48-0.36-0.37-0.38-0.44-0.45-0.42-0.44-0.42-0.36-0.32-0.31-0.33-0.29
EPS Actual-1.16-1.39-0.93-1.55-0.40-0.31-0.32-0.44-0.44-0.44-0.46-0.49-0.12-0.39-0.47-0.44-0.38-0.39-0.44-0.35-0.30-0.28-0.26-0.24-
Surprise---0.28%-469.05%-66.67%13.89%5.88%-22.22%8.33%4.35%6.12%-2.08%66.67%-5.41%-23.68%0.00%15.56%7.14%0.00%16.67%16.67%13.29%16.13%27.27%-
Timing---After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap134.01M
Enterprise Value53.17M
Trailing P/E0.00
Forward P/E0.00
Price / Sales13.35
Price / Book1.42
EPS-1.08
Book Value0.926
Revenue (TTM)10.04M
Gross Profit (TTM)-73.82M
EBITDA-104.61M
Profit Margin0.00%
Operating Margin-1690.39%
Return on Equity-78.27%
Return on Assets-36.85%
Shares Outstanding107.21M
Shares Float102.91M
Beta2.28
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 9 analystsTarget 11.86
  • Strong Buy
    5
  • Buy
    2
  • Hold
    2

Ownership Breakdown

Institutions
44.90%
Insiders
8.24%
Retail / Other
46.86%

Top Institutional Holders

  • Pfizer Inc
    4.69M4.38%
  • Vanguard Capital Management, LLC
    3.77M3.51%
  • Renaissance Technologies Corp
    2.59M2.42%
  • Kynam Capital Management, LP
    2.50M2.33%
  • BlackRock Inc
    2.14M2.00%
  • Bank of America Corp
    1.30M1.21%
  • Marshall Wace Asset Management Ltd
    1.21M1.12%
  • Two Sigma Investments LLC
    1.05M0.98%
  • Geode Capital Management, LLC
    1.02M0.95%
  • Dimensional Fund Advisors, Inc.
    975.33K0.91%
  • Mackenzie Investments
    942.79K0.88%
  • Acadian Asset Management LLC
    925.04K0.86%
  • Susquehanna International Group, LLP
    836.90K0.78%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    3.01M2.81%
  • iShares Russell 2000 ETF
    2.26M2.11%
  • ACATIS Datini Valueflex Fonds A
    2.00M1.87%
  • Canada Life US Small-Mid Cap Growth F
    1.44M1.35%
  • Selectra J. Lamarck Biotech A
    1.43M1.33%
  • Fidelity Small Cap Index
    998.58K0.93%
  • iShares Russell 2000 Value ETF
    871.69K0.81%